• Save
Analysis On Financial Statement Of Pharmaceutical  Co. In Pakistan
Upcoming SlideShare
Loading in...5
×

Like this? Share it with your network

Share

Analysis On Financial Statement Of Pharmaceutical Co. In Pakistan

  • 8,479 views
Uploaded on

Analysis on the financial Statemnet of GSK, Aventis, Searle and Ferozsons.

Analysis on the financial Statemnet of GSK, Aventis, Searle and Ferozsons.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
  • gud job
    Are you sure you want to
    Your message goes here
  • nice work))))))))))))))))))))
    how can i download this?
    anybody help me out
    or send this ppt at
    ganesh.iobm@gmail.com

    thanx
    Are you sure you want to
    Your message goes here
No Downloads

Views

Total Views
8,479
On Slideshare
8,439
From Embeds
40
Number of Embeds
3

Actions

Shares
Downloads
0
Comments
2
Likes
7

Embeds 40

http://www.slideshare.net 27
http://www.slideee.com 12
http://www.linkedin.com 1

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. GSK Aventis Searle Ferozsons Analysis on Financial Statements of Pharmaceutical Companies in Pakistan
  • 2. Introduction to Pharmaceutical Industry
    • Pakistan meets 80% of its domestic demand of medicines from local production and 20% through imports.
    • The pharmaceuticals market size is Rs. 70 Billion (US $ 1.2 Billion), approximately.
    • Introduction to GSK
    • GlaxoSmithKline Pakistan Limited was created on January 1st 2002 through the merger of SmithKline and French of Pakistan Limited, Beecham Pakistan (Private) Limited and Glaxo Wellcome (Pakistan) Limited- standing today as the largest pharmaceutical company in Pakistan
  • 3.
    • GSK facts
    • GSK dedicated to R&D for 80 years
    • Cost of bringing a medicine to market: $800 million (Rs 4.8 billion)
    • Average length of time to discover new drug: 10-15 years
    • 5 out of every 10,000 compounds investigated reach clinical trial phase and only 1 of those gets approved for patient use.
    • GSK has industry's most extensive portfolio of R&D projects for diseases affecting developing countries
  • 4. Horizontal Analysis
  • 5.  
  • 6.  
  • 7.  
  • 8.  
  • 9.  
  • 10.  
  • 11.  
  • 12. VERTICAL ANALYSIS
  • 13.  
  • 14.  
  • 15.  
  • 16. CASH FLOWS
  • 17.  
  • 18.  
  • 19.  
  • 20.  
  • 21. RATIOS
  • 22.  
  • 23.  
  • 24.  
  • 25.  
  • 26.  
  • 27.  
  • 28.  
  • 29.  
  • 30. Users of Financial Statements
    • Investors Point of view
    • Creditors point of view
    • Employees point of view
    • Government point of view
  • 31. Other Factors
    • Company Reputation
    • Contribution to Society
    • Stakeholder engagement